Why did SYRA's Q4 earnings fall short of forecasts?

Syra Health's Q4 earnings fell short of forecasts due to a combination of factors: 1. **Revenue Shortfall**: The company's total revenue for Q4 was $2.01 million, which was significantly lower than the expected revenue. This shortfall can be attributed to a decline in stock price and market conditions. 2. **Stock Price Decline**: Syra Health's stock hit a 52-week low, reaching a price of $0.14, reflecting a substantial drop of -79.7% over the past year. This decline indicates a challenging period for the company, which has affected investor confidence and potentially impacted financial performance. 3. **Market Challenges**: The company is grappling with a challenging market environment, which has further compounded the issues related to stock price and revenue shortfall. Despite strong revenue growth of 44.73% in the last twelve months, the company's stock has been under pressure, likely due to broader industry headwinds and economic uncertainties. In summary, Syra Health's Q4 earnings fell short of forecasts due to a combination of lower-than-expected revenue, stock price decline, and challenging market conditions.